Gland Pharma share price
You have to be logged in to add this to Watchlist.- ₹1,805.55(-0.50%)November 18, 2025 10:26:14 AM IST
- NSE
- BSE
- Vol : 12.72K (NSE + BSE)Last 20 day avg : 132.67 K
Gland Pharma is trading -0.50% lower at Rs 1,805.55 as compared to its last closing price. Gland Pharma has been trading in the price range of 1,822.05 & 1,794.05. Gland Pharma has given 2.02% in this year & -3.50% in the last 5 days. Gland Pharma has TTM P/E ratio 41.52 as compared to the sector P/E of 28.85.There are 13 analysts who have initiated coverage on Gland Pharma. There are 3 analysts who have given it a strong buy rating & 3 analysts have given it a buy rating. 3 analysts have given the stock a sell rating.The company posted a net profit of 183.68 Crores in its last quarter.Listed peers of Gland Pharma include Ipca Laboratories (-0.50%), Ajanta Pharma (-1.31%), Gland Pharma (-0.50%).The Mutual Fund holding in Gland Pharma was at 30.19% in 30 Sep 2025. The MF holding has decreased from the last quarter. The FII holding in Gland Pharma was at 7.90% in 30 Sep 2025. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Updated on Nov 18, 2025, 04:57 AM UTC
- BetaLow volatility0.56Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.03The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldInline with the industry0.98Annual dividends as a percentage of the stock price.
- P/BLower than historical values3.29The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/ELower than historical values38.15Price-to-earnings ratio based on trailing 12-month earnings
- PEG RatioIndicates undervaluation-2.27The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in September quarter by 5.76% from Rs 1486.88 crore to Rs 1405.83 crore, year-on-year
- The company has grown its September quarter profit by 12.32% from Rs 163.53 crore to Rs 183.68 crore, year-on-year
- The debt to equity of the company is lower than the industry median
- Company can comfortably pay off its interest obligations with its earnings
- R1
- 2,075.57
- R2
- 2,178.98
- R3
- 2,327.97
- S1
- 1,823.17
- S2
- 1,674.18
- S3
- 1,570.77
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Ipca Laboratories | Bullish | 1,455.70 | -0.50 | 37,221.59 | 40.79 | 5.17 | 0.28 | 8.55 |
| Ajanta Pharma | Bearish | 2,470.50 | -1.31 | 30,825.94 | 35.77 | 8.67 | 2.05 | 0.92 |
| Gland Pharma | Moderately Bearish | 1,805.55 | -0.50 | 29,736.12 | 44.21 | 3.37 | 0.96 | 1.17 |
| Wockhardt | Bearish | 1,347.00 | -1.59 | 21,886.81 | - | 6.51 | - | 30.00 |
| Piramal Pharma | Bearish | 192.25 | -1.69 | 25,528.69 | 177.36 | 3.3 | 0.07 | 40.78 |
- Promoter(s) holds a high stake in the company at 51.83%
- FIIs are invested in this company
- FIIs holding has increased by 0.51 percentage points from previous quarter
Mutual Funds holding has decreased by 0.48 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-11-03 | Quarterly Results |
| 2025-08-05 | Quarterly Results |
| 2025-05-20 | Audited Results & Final Dividend |
| 2025-02-03 | Quarterly Results |
| 2024-11-04 | Quarterly Results |
- IndustryBiotechnology & Drugs
- ISININE068V01023
- BSE Code543245
- NSE CodeGLAND
Gland Pharma is trading at 1805.55 as on Tue Nov 18 2025 04:56:14. This is -0.50% lower as compared to its previous closing price of 1814.60.
The market capitalization of Gland Pharma is 29736.12 Cr as on Tue Nov 18 2025 04:56:14.
The average broker rating on Gland Pharma is Hold. The breakup of analyst rating is given below -
- 3 analysts have given a strong buy rating
- 3 analysts have given a buy rating
- 3 analysts have given a hold rating
- 3 analysts have given a sell rating
- 1 analysts have given a strong sell rating
The 52 wk high for Gland Pharma is 2130.00 whereas the 52 wk low is 1200.00
Gland Pharma can be analyzed on the following key metrics -
- TTM P/E: 41.52
- Sector P/E: 28.85
- Dividend Yield: 0.99%
- D/E ratio: 0.03
Gland Pharma reported a net profit of 698.53 Cr in 2025.
The Mutual Fund Shareholding was 30.19% at the end of 30 Sep 2025.